Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization (Mona-Lisa)

• Patient with a first TACE (naive) or not, regardless of the number of previous procedures
• Patient naïve or on a new line of oncological treatment, regardless of the number of previous lines of treatment.

Inclusion Criteria:

• Age ≥ 18 years
• HCC diagnosed on consensus radiological criteria in cirrhotic patients (EASL-EORTC 2012): helical CT or MRI with triple arterial, portal, and late acquisition. The diagnosis is based on the presence of hypervascularization at the early arterial time (wash-in) with wash-out (hypodensity or hypointensity compared with non-tumor liver parenchyma) at the portal phase or late phase compared with non-tumor parenchyma.
• Histologically diagnosed HCC in the absence of an imaging diagnosis
• Patient with a first TACE (naive) or not, regardless of the number of previous procedures
• Patient naïve or on a new line of oncological treatment, regardless of the number of previous lines of treatment.
• Treatment decision validated by the digestive oncology staff.
• Patient having read and understood the information letter and signed the informed consent.
• Patient follow-up performed at the Charles Nicolle University Hospital in Rouen.

Exclusion Criteria :

• Other active cancer or hematological malignancy, currently being treated
• Patient not affiliated to the social security system
• Pregnant woman or woman in labour or breastfeeding
• Person deprived of liberty by an administrative or judicial decision
• Person placed under court protection